Maravai LifeSciences Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Maravai LifeSciences Holdings generated cash of $126,224,000, which is less than the previous year. Cash used in financing activities reached the amount of -$61,090,000 last year. Net change in cash is therefore -$57,176,000.
Cash Flow
| 2018 | -186K | -3.45M | -9.16M |
|---|---|---|---|
| 2019 | 24.11M | -17.14M | -4.16M |
| 2020 | 152.18M | 6.06M | 53.21M |
| 2021 | 368.57M | 105.65M | -159.04M |
| 2022 | 535.97M | -267.61M | -187.49M |
| 2023 | 126.22M | -122.31M | -61.09M |
MRVI Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 632.13M | 551.27M | 236.18M | 24.7M | 21.86M | 34.73M |
Operating activities | ||||||
Net income | -119.02M | 490.66M | 469.25M | 78.81M | -5.20M | -16.91M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 48.78M | 38.10M | 24.75M | 25.83M | 24.08M | 22.34M |
Stock-based compensation expense | 34.58M | 18.67M | 10.45M | 24.62M | 1.67M | 0 |
| Deferred income tax benefit | 34.58M | 18.67M | 10.45M | 24.62M | 1.67M | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 84.39M | -22.27M | -70.39M | -33.14M | -1.88M | -4.14M |
Inventories | 649K | 9.45M | -21.57M | -19.09M | 106K | 2.31M |
Accounts payable | 5.28M | -1.57M | 676K | 1.17M | 2.47M | -871K |
Cash generated by operating activities | 126.22M | 535.97M | 368.57M | 152.18M | 24.11M | -186K |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -65.55M | -17.09M | -14.85M | -25.40M | -17.14M | -3.61M |
Acquisitions Net | -69.62M | -238.34M | 119.95M | -3.02M | 0 | 160K |
Cash generated by investing activities | -122.31M | -267.61M | 105.65M | 6.06M | -17.14M | -3.45M |
Financing activities | ||||||
Common Stock Issued | 0 | 2.35M | 1.70M | 1.75B | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -20K | 0 | 0 | -1.45B | -227K | -9K |
Repayments of term debt | -5.77M | -5.44M | -6M | -412.07M | -2.64M | -255.20M |
Cash used in financing activities | -61.09M | -187.49M | -159.04M | 53.21M | -4.16M | -9.16M |
Net Change In Cash | -57.17M | 80.86M | 315.08M | 211.48M | 2.83M | -12.87M |
Cash at end of period | 574.96M | 632.13M | 551.27M | 236.18M | 24.7M | 21.86M |
| Data source | Data source | Data source | Data source |